NCT03434366 is a Phase 2 clinical trial of ketamine and dexmedetomidine in Autism Spectrum Disorder, sponsored by Guangzhou Women and Children's Medical Center.

Who is sponsoring NCT03434366?

NCT03434366 is sponsored by Guangzhou Women and Children's Medical Center.

What drugs are being tested in NCT03434366?

Interventions in NCT03434366: ketamine and dexmedetomidine, ketamine, Saline.

What condition does NCT03434366 study?

NCT03434366 studies Autism Spectrum Disorder.

Is NCT03434366 still recruiting?

NCT03434366 is currently suspended. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT03434366

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder

Suspended Phase 2 Last updated 12 April 2022

What this trial tests

Phase 2 trial testing ketamine and dexmedetomidine in Autism Spectrum Disorder in 50 participants. Suspended.

Timeline

20 January 2018

Primary endpoint
30 December 2023

30 December 2023

Quick facts

Lead sponsor	Guangzhou Women and Children's Medical Center
Phase	Phase 2
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	20 January 2018
Primary completion	30 December 2023
Estimated completion	30 December 2023
Sites	1 location across China

Drugs / interventions tested

ketamine and dexmedetomidine — full drug profile →
ketamine (ketamine) — full drug profile →
Saline

Conditions studied

Autism Spectrum Disorder — all drugs for Autism Spectrum Disorder →

Sponsor

Guangzhou Women and Children's Medical Center

Who can join

Adults 2 to 15, any sex, with Autism Spectrum Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Autism spectrum disorder (ASD) is a life-long neurodevelopmental disorder characterized by qualitative abnormalities in reciprocal social interactions and patterns of communication, and by a restricted, stereotyped, repetitive repertoire of interests and activities. The use of medications in adolescents and young adults with ASD is extremely common. However, few data address the effectiveness and harms of medications specifically in this population. The purpose of the study is to determine the efficacy and safety of intranasal ketamine with dexmedetomidine in children with ASD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Autism Spectrum Disorder

Currently open trials in the same condition.

NCT07324057 — The Effects of Preoperative Intranasal Administration of Dexmedetomidine and Esketamine on Negative Postoperative Behavi · NA · recruiting
NCT07493096 — Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disor · recruiting
NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
NCT07524192 — A Self-Instructional Online Program for Early Childhood and Elementary Teachers Supporting Autistic Children and Childre · NA · recruiting
NCT07432776 — Effect of an 8-Week Pickleball Program for Adults With Autism: A Feasibility Trial With a Delayed-Control Design · EARLY_PHASE1 · recruiting

Other Guangzhou Women and Children's Medical Center trials

Trials by the same sponsor.

NCT07190001 — YOLT-204 in Patients With Hemoglobinopathies · EARLY_PHASE1 · not yet recruiting
NCT06904729 — Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children · Phase 3 · recruiting
NCT06948994 — A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Di · Phase 1, PHASE2 · not yet recruiting
NCT06856759 — Single-Dose AAV-MECP2 Safety/Tolerability and Efficacy in Rett Syndrome · EARLY_PHASE1 · recruiting
NCT06731205 — Long-term Renal Prognosis of Neonatal Acute Kidney Injury · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03434366 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Women and Children's Medical Center
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03434366.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing